Drugs need to be metabolized through a series of enzymes in the body. Some drugs have low activity after the enzyme metabolism. And some drugs transform into the active form after metabolism. Among them, transfering enzymes of uridine diphosphate glucuronyl are responsible for reducing toxicity of some toxic substances or drugs with a transporter and excreting it. The activity of this enzyme is not the same in different people. Some enzyme activities are strong and the speed of excreting poison is fast. On the contrary, some enzyme activities are weak. So the concentration of poison in the body will maintain at a high level.

Different metabolic types between different people are due to the different gene encoding of this enzyme, so that the pharmaceutical raw materials will play different roles or produce different adverse effects of the medication of people with different Irinotecan is an anticancer drug used in clinical trials. Its active ingredient SN-38 is an active enzyme. It becomes SN-38G with adding a G. Then the toxicity is reduced and excreted. UGT1A1 enzyme activity in patients with normal timely metabolism, the drug not only plays the role of anti-tumor. It does not produce excessive toxicity for the human body.

Patients with low UGT1A1 activity, SN-38 in the body to maintain a higher level will give drug users a strong toxicity. Under normal circumstances, the instructions given by doctors dose is the most suitable dose distribution are relatively small, less activity is not considered. However, in the application of anticancer drugs, people can not ignore the adverse drug reaction in this part. In fact, in our daily life, people are really concerned about irinotecan price.

Some patients with irinotecan, given the normal recommended dose of time will happen after very severe neutropenia and diarrhea. The patient can not tolerate the very painful and even fatal treatment process. Therefore, before applying irinotecan, it is best to UGT1A1 genotype to predict the enzyme activity, decreased activity of patients should be appropriate to reduce the dose, while a number of patients with genotypes (enzyme has a particularly low activity) should try to avoid using this drug.

Irinotecan is used in the treatment of adult metastatic colorectal cancer. And for the patients with failures of 5-Fu chemotherapy, it can be used as a second-line treatment. At the same time, phased observations of a variety of clinical trials in gastric cancer, esophageal cancer, extensive stage small cell lung cancer are underway. In the point of view of interim observations, irinotecan has a good clinical application prospect and it is worth close attention.Source:http://www.cospcn.com